Company: LCTX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001193125-25-269599
Chunk: 8

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 8
Chunk 8
---
 in patients in Cohort 4 (less advanced GA) measured at month 12 remain evident through month 36 following subretinal administration of OpRegen cell therapy; (ii) improvement in BCVA and outer retinal structure in patients with extensive OpRegen bleb coverage of their GA area was greater than in patients with limited coverage and persisted through month 36; (iii) in those patients with extensive OpRegen cell therapy coverage of atrophic areas at the time of surgical delivery, the mean change in BCVA was +9.0 ETDRS letters for those completing 3-year follow-up (compared to +7.4 ETDRS letters at 24 months) (n=5); and (iv) these data suggest that